Clinical trial
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy…
NCT00307736 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00307736 |
|---|---|
| Title | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer |
| Official title | A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer, Adenocarcinoma of the Rectum |
| Intervention type | Drug, Procedure |
| Interventions | 5-fluorouracil, bevacizumab, erlotinib, External beam radiation therapy (EBRT) |
| Enrollment | 32 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Mar 28, 2006 |
| Last update posted | May 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: